Abstract
Epidermal growth factor receptors (EGFR) are over-expressed in many different types of cancer, thus, are logical targets for both diagnosis and therapy. Antibodies and antibody fragments targeting the extracellular EGF receptor and small molecules targeting the intracellular tyrosine kinase (TK) part of EGFR have been developed as possible diagnostic EGFR imaging agents. Recently, a 12-amino acid peptide, GE11, was identified using phage display screening to have high affinity for EGFR (Kd=22nM). Reported in vitro and in vivo characteristics of GE11 suggest that positron-labeled GE11 may be a useful PET imaging agent in selecting patients with EGFR-rich tumors who can most benefit from anti- EGFR therapy. To enable the exploration of this possibility, positron emitting [64Cu]Cu-NOTA-Bn-GE11 was prepared for further evaluation as PET EGFR imaging agent.
Keywords: Epidermal growth factor receptor (EGFR), GE 11, cancer, PET imaging, GE11-Bn-NOTA, Radiochemistry, MRI Scans
Current Radiopharmaceuticals
Title: Synthesis of [64Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Volume: 5 Issue: 1
Author(s): Onofre T. DeJesus
Affiliation:
Keywords: Epidermal growth factor receptor (EGFR), GE 11, cancer, PET imaging, GE11-Bn-NOTA, Radiochemistry, MRI Scans
Abstract: Epidermal growth factor receptors (EGFR) are over-expressed in many different types of cancer, thus, are logical targets for both diagnosis and therapy. Antibodies and antibody fragments targeting the extracellular EGF receptor and small molecules targeting the intracellular tyrosine kinase (TK) part of EGFR have been developed as possible diagnostic EGFR imaging agents. Recently, a 12-amino acid peptide, GE11, was identified using phage display screening to have high affinity for EGFR (Kd=22nM). Reported in vitro and in vivo characteristics of GE11 suggest that positron-labeled GE11 may be a useful PET imaging agent in selecting patients with EGFR-rich tumors who can most benefit from anti- EGFR therapy. To enable the exploration of this possibility, positron emitting [64Cu]Cu-NOTA-Bn-GE11 was prepared for further evaluation as PET EGFR imaging agent.
Export Options
About this article
Cite this article as:
T. DeJesus Onofre, Synthesis of [64Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors, Current Radiopharmaceuticals 2012; 5 (1) . https://dx.doi.org/10.2174/1874471011205010015
DOI https://dx.doi.org/10.2174/1874471011205010015 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
Current Medicinal Chemistry Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis
Anti-Cancer Agents in Medicinal Chemistry Distinct Roles of sAPP-α and sAPP-β in Regulating U251 Cell Differentiation
Current Alzheimer Research Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Recent Research Progress on Magnetic Nanocomposites with Silica Shell Structures Preparation and Nanotheranostic Applications
Recent Patents on Nanotechnology Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Cell-penetrating Peptide-based Intelligent Liposomal Systems for Enhanced Drug Delivery
Current Pharmaceutical Biotechnology Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Development of Novel Therapeutic Strategies for Lung Cancer: Targeting the Cholinergic System
Current Medicinal Chemistry Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Chemical Composition and Biological Activities of <i>Croton delpyi, Croton decalvatus</i> and <i>Croton caudatus</i>
The Natural Products Journal ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology